ERBB2 and breast cancer: Their study analyzed 9732 women with HER2-negative BC, and they found high-quality evidence to indicate that there is no significant difference in CHF diagnosis between patients treated with adjuvant TC vs. anthracycline–taxane chemotherapy [36].